Synaptogenix Inc (SNPX)

[Cyosol]

I think what a lot of people seem to miss is that the MOA of Bryostatin 1 inherently means that they only need one good trial to prove that this drug can work for multiple indications.

AD, Fragile X, MS, PD, TBI, autism and depression all have the same symptom, not the same cause but the same symptom, which is dysfunctional/destroyed synapses in the brain. There is a good reason for why they are pursuing all these indications with the same drug. There is a good reason for why they have shown improvements in mice suffering from all these different disorders by using the same drug.

AD is just one of many neurological disorders that involve brain damage and this is a drug that is meant to work by repairing brain damage, no matter how that damage is caused.

I firmly believe that one good trial is all it takes to prove that the MOA works and can be used effectively across indications.

In the latest paper by Dr. Wender he once again proves that PKC activation is what drives the positive changes in mouse brains, and Synaptogenix currently owns the biggest patent portfolio and drug pipeline for PKC activators that I know of.

It's not just an Alzheimer's drug. It's an entire platform of PKC activators meant to reverse brain damage by activating the growth of new brain cells, and the company never seems quite able to get that message across to the market which thinks that this company is only worth the cash it has.